Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07577115
Active, not recruiting Observational

Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.

NCT07577115 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Clinico Humanitas
Phase
Observational
Started
2026-04-01
Last updated
2026-05-11

Condition(s) studied

Interstitial Lung Disease Due to Systemic Disease (Disorder)Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)Exposure OccupationalOccupational ExposureExposure to Household Air PollutionExposure to Chemical Pollution, OccupationalExposure to Environmental PollutionIdiopathic Pulmonary Fibrosis (IPF)Progressive Pulmonary FibrosisHypersensitivity PneumonitisILD Progression and Exposure to Indoor Environnemental RiskILD Progression and Exposure to Outdoor PolluantsILD

Investigational drug(s) / intervention(s)

standard interview

standard interview: standard interview to detect relevant exposures

Study summary

The OCEAN-ILD study is designed to prospectively evaluate the prevalence and clinical relevance of environmental and occupational exposures in a large Italian cohort of patients affected by any ILD, using a standardised exposure questionnaire applied across multiple centres.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years old * Any gender * Any race * Ability to give informed consent according to ICH/EU GCP, and national/local regulations. * New diagnosis of ILD according to classified according to American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias Exclusion Criteria: * Sarcoidosis * Primary diagnosis of COPD and/or Asthma

Primary outcome measure(s)

  • Frequency of any exposure (environmental and/or occupational) in ILD patients. — 5 years
    to assess the frequency of environmental and/or occupational exposures among patients with newly diagnosed ILD
  • Use of a standardized questionnaire in all the centers — 5 years
    To standardise exposure assessment through a structured questionnaire across participating centres

Trial sites (1)

FacilityCityRegionStatus
Humanitas research hospital Rozzano Italy

More Istituto Clinico Humanitas trials in Italy

Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg (PATTERN) Active, not recruiting
Critical Illness Weakness Outside the Intensive Care Unit. Recruiting
Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes. Recruiting
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA Recruiting
AI for Head Neck Cancer Treated With Adaptive RadioTherapy (RadiomicART) Active, not recruiting

Other trials for the same condition

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Active, not recruiting
Hereditary Influences on Pulmonary Fibrosis Trajectories Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis Active, not recruiting
Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07577115 on ClinicalTrials.gov ↗ ← All trials in Italy